Gonadotropin-releasing hormone agonist versus HCG for oocyte triggering in antagonist-assisted reproductive technology - Wikidata - awgldk - TriplyDB

Gonadotropin-releasing hormone agonist versus HCG for oocyte triggering in antagonist-assisted reproductive technology

Gonadotropin-releasing hormone agonist versus HCG for oocyte triggering in antagonist-assisted reproductive technology

http://www.wikidata.org/entity/Q24193015

about

Assisted reproductive technology: an overview of Cochrane Reviews Gonadotrophins for ovulation induction in women with polycystic ovarian syndrome Assisted reproductive technology: an overview of Cochrane Reviews Resurgence of Minimal Stimulation In Vitro Fertilization with A Protocol Consisting of Gonadotropin Releasing Hormone-Agonist Trigger and Vitrified-Thawed Embryo Transfer Oocyte, embryo and blastocyst cryopreservation in ART: systematic review and meta-analysis comparing slow-freezing versus vitrification to produce evidence for the development of global guidance Revisiting ovarian hyper stimulation syndrome: Towards OHSS free clinic GnRH Agonist Triggering of Ovulation Replacing hCG: A 30-Year-Old Revolution in IVF Practice Led by Rambam Health Care Campus Pharmacokinetic, pharmacodynamic, and clinical aspects of ovulation induction agents: A review of the literature GnRH Agonist Trigger and LH Activity Luteal Phase Support versus hCG Trigger and Conventional Luteal Phase Support in Fresh Embryo Transfer IVF/ICSI Cycles-A Systematic PRISMA Review and Meta-analysis Efficacy of Kisspeptin-54 to Trigger Oocyte Maturation in Women at High Risk of Ovarian Hyperstimulation Syndrome (OHSS) During In Vitro Fertilization (IVF) Therapy.Dopamine agonist inhibits vascular endothelial growth factor protein production and secretion in granulosa cells.Utrogestan as an effective oral alternative for preventing premature luteinizing hormone surges in women undergoing controlled ovarian hyperstimulation for in vitro fertilization.Best practices for controlled ovarian stimulation in in vitro fertilization Interventions for the prevention of OHSS in ART cycles: an overview of Cochrane reviews.Progesterone administration for luteal phase deficiency in human reproduction: an old or new issue?Why more is less and less is more when it comes to ovarian stimulation.Gonadotropin-releasing hormone agonist for oocyte triggering in endometrial preparation of letrozole stimulation protocols does not affect clinical outcome of frozen-thawed embryo transfer Gonadotropin-releasing hormone agonist trigger is a better alternative than human chorionic gonadotropin in PCOS undergoing IVF cycles for an OHSS Free Clinic: A Randomized control trial.The use of gonadotropin-releasing hormone antagonist post-ovulation trigger in ovarian hyperstimulation syndrome.The high responder: a review of pathophysiology and outcomes during IVF treatment.An update on the prevention of ovarian hyperstimulation syndrome.The medical and ethical challenges of fertility preservation in teenage girls: a case series of sickle cell anaemia patients prior to bone marrow transplant.Volume expanders for the prevention of ovarian hyperstimulation syndrome.The state of "freeze-for-all" in human ARTs.GnRH agonist trigger with intensive luteal phase support vs. human chorionic gonadotropin trigger in high responders: an observational study reporting pregnancy outcomes and incidence of ovarian hyperstimulation syndrome.GnRH agonist with low-dose hCG (dual trigger) is associated with higher risk of severe ovarian hyperstimulation syndrome compared to GnRH agonist alone.Comparison of two different dosage of GnRH agonist as ovulation trigger in oocyte donors: a randomized controled trial Fertility with early reduction of ovarian reserve: the last straw that breaks the Camel's back.Comparison of a 'freeze-all' strategy including GnRH agonist trigger versus a 'fresh transfer' strategy including hCG trigger in assisted reproductive technology (ART): a study protocol for a randomised controlled trial.Cancer and fertility preservation: international recommendations from an expert meeting.A novel oocyte maturation trigger using 1500 IU of human chorionic gonadotropin plus 450 IU of follicle-stimulating hormone may decrease ovarian hyperstimulation syndrome across all in vitro fertilization stimulation protocols.Oncofertility in sarcoma patients.Low-dose hCG as trigger day and 35 hr later have different ovarian hyperstimulation syndrome occurrence in females undergoing In vitro fertilization: An RCT.Dual trigger with gonadotropin-releasing hormone agonist and recombinant human chorionic gonadotropin improves in vitro fertilization outcome in gonadotropin-releasing hormone antagonist cycles.Repeat Dose of Gonadotropin-releasing Hormone Agonist Trigger in Polycystic Ovarian Syndrome Undergoing In Vitro Fertilization Cycles Provides a Better Cycle Outcome - A proof-of-concept Study.Fresh versus frozen embryo transfer after gonadotropin-releasing hormone agonist trigger in gonadotropin-releasing hormone antagonist cycles among high responder women: A randomized, multi-center study.The dual trigger study: Rationale and study design of a prospective double-blind randomized clinical trial comparing pregnancy rates after co-administration of low dose hCG at the time of GnRH agonist trigger or 35 h later for the prevention of OHSS Dual trigger with gonadotropin-releasing hormone and human chorionic gonadotropin for poor responders Comparison of modified agonist, mild-stimulation and antagonist protocols for in vitro fertilization in patients with diminished ovarian reserve.

P2860

Q24186642-BFDF8F46-827A-4721-B7C8-EEEEE6315A3D Q24187261-E504FC8B-0753-40F3-8EE1-67C72EDECEE0 Q24187504-3ABC9446-1B6F-4B1F-9014-6F2E0A8711B7 Q26738612-63471D2A-5C3C-4171-8D00-24AD9ED2051F Q28077375-177E6A62-E8C4-412C-A101-C3B2C80C9EFC Q28084432-2553B5CD-9215-4C65-9DE5-64CC9D463F8B Q33633426-33DAE4A1-66B4-451B-AA87-B651C063F954 Q33743109-54A4DAA7-DA58-4712-A458-1BBEEB5A21E0 Q33770533-C90EA54A-2858-4E52-86D8-40FED8DB0397 Q36060453-D9FA66B5-0D03-4811-B455-DF74B815826C Q36071521-83B1C58D-374F-49F7-91D7-F826CC0871B2 Q36193975-82CEA9CD-4F6E-482F-B274-FF5E6B2CCEA9 Q36233245-94431E67-97EC-405C-86D2-318F1F553AFA Q36256879-D94ECE92-D625-4E43-AA27-C62C9C4B8221 Q36301761-0985D480-F475-449B-BAE2-0447565E7091 Q36378491-1688448B-001D-45EB-87E6-C7249A55F055 Q36412114-121FB9E8-526E-4314-AF0B-28C282CC5516 Q37350477-A9A67A5A-B493-4920-BD65-7AB5A9E12BD3 Q38631311-E98B3476-87AB-42DA-8010-E94567DFFD89 Q38716011-16414C02-CEBE-46C0-8539-304468A5CF53 Q38829575-59657949-5EB6-4407-B950-C70E06B6BA04 Q38876221-FCEEF1C6-D567-4B50-93DD-00370CE3AD61 Q38941693-4A21F705-BAC8-4B7C-B633-33C17CD28703 Q38954609-9917F6DD-9CD4-4791-8AA3-45D23A992F42 Q40568355-4C584780-80DD-40CC-B772-87DE72FA7516 Q41011753-FDE0898C-C0A5-4933-921C-A0EDEA5CC43C Q41545744-71DE10A0-CDE5-4594-9FC0-CD5AB6DC3ED1 Q42375163-4D442FFC-D046-4F8C-834E-B3C362CD95CB Q42697462-257ED11A-1260-41BB-AE1B-69D09DD792D4 Q43106184-4AC1D77A-5695-4174-AF88-FC6EEF74C4BC Q46788717-B85BE9E7-B649-4F6C-A2FA-9F2F8BF51A27 Q47096741-83F797F5-F98E-4570-90BC-5E92BC977D76 Q48501929-30200FE1-6F01-47BA-8C09-FB68C041BFFE Q48550093-3511D281-51DA-4343-BC8D-C46D7C296CAF Q49683764-3F430184-43EB-493A-AF68-0F294215B98A Q55116047-380AB6BC-8843-4C61-B5B9-5A097437522A Q55255517-FBBDD268-AFFA-4D6C-B718-7FB800A51E14 Q55311441-BF33DD35-D8D3-4E05-8527-1AAE07629EA5 Q55449124-56192974-C339-4CD7-AEA3-CB6A57F0F9B8

P2860

Gonadotropin-releasing hormone agonist versus HCG for oocyte triggering in antagonist-assisted reproductive technology

http://www.wikidata.org/entity/Q24193015

description

2014 nî lūn-bûn

@nan

2014 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Gonadotropin-releasing hormone ...... sisted reproductive technology

@ast

Gonadotropin-releasing hormone ...... sisted reproductive technology

@en

Gonadotropin-releasing hormone ...... sisted reproductive technology

@nl

type

label

Gonadotropin-releasing hormone ...... sisted reproductive technology

@ast

Gonadotropin-releasing hormone ...... sisted reproductive technology

@en

Gonadotropin-releasing hormone ...... sisted reproductive technology

@nl

prefLabel

Gonadotropin-releasing hormone ...... sisted reproductive technology

@ast

Gonadotropin-releasing hormone ...... sisted reproductive technology

@en

Gonadotropin-releasing hormone ...... sisted reproductive technology

@nl

P1433

Q24193015-7EF4816F-E184-4039-8B02-AF86BA86E719

P1476

Q24193015-7D874500-DE65-4B18-9BEB-C507027B0705

P2093

Q24193015-06D6635F-313A-4F9F-B038-FE440515726C

Q24193015-167FB348-1E58-4E2E-A5D6-538362CDDE93

Q24193015-1BCC1828-1F4F-42DC-B09F-EFD701B192C6

Q24193015-26E4FC33-9050-4369-A1CC-D615DB95A5FF

Q24193015-5CC92EAB-C038-47F0-ACFE-AF006CDA1E2E

Q24193015-C12052BB-68C0-496B-9CCC-51D5C47022B2

P2860

Q24193015-01847FCB-130F-40D6-8D79-A1C801F1F985

Q24193015-026C9CF7-1678-4AAF-916F-9BE734FB9A08

Q24193015-0BDF7A08-D145-49D4-86B8-65E4BCC19B80

Q24193015-12685102-A44F-4EAC-AF55-9F72755B0DB1

Q24193015-16351BA3-F406-4BD7-95AB-C354512FFF2D

Q24193015-1719F2C1-5513-4079-AA7A-754E077D6411

Q24193015-1DB2D8D2-5DA2-4F3A-9118-D0CAEC4A1A96

Q24193015-1EEA51CF-2681-4971-B1A7-3A8BC39B8D97

Q24193015-1FE6EC53-AE71-4A18-9299-455DA1618EDF

Q24193015-2DBC658D-CC54-4818-A497-AFBE6805D77F

P31

Q24193015-FAB9B088-BCD0-4AAD-8122-13A478953F9A

Q24193015-d58cb361-f51b-42e8-b9ac-9ad0483fcb64

P3181

Q24193015-4AB6426D-008E-465E-A84B-39D0A262EAC7

P356

Q24193015-C6486C71-58A6-415E-9BA9-0F416CBDAEED

P50

Q24193015-1127F821-B9F4-4579-9902-5E5599E29201

Q24193015-255CACBC-D84F-4516-9466-447A12CB2637

P577

Q24193015-73615E4E-6C3E-4A18-8CDE-DC275CB229C7

P698

Q24193015-EE876372-92D8-4C2E-8384-AC3A714E9157

P3181

P356

14651858.CD008046.PUB4

P1433

Cochrane Database of Systematic Reviews

P1476

Gonadotropin-releasing hormone ...... sisted reproductive technology

@en

P2093

Georg Griesinger

http://www.w3.org/2001/XMLSchema#string

Hesham G Al-Inany

http://www.w3.org/2001/XMLSchema#string

Ismail Aboulfoutouh

http://www.w3.org/2001/XMLSchema#string

Mohamed AFM Youssef

http://www.w3.org/2001/XMLSchema#string

Mohamed Nagi Mohesen

http://www.w3.org/2001/XMLSchema#string

Monique H Mochtar

http://www.w3.org/2001/XMLSchema#string

P2860

Pregnancy and birth after GnRH agonist treatment for induction of final oocyte maturation in a woman undergoing ovarian stimulation for ICSI, using a GnRH antagonist (Orgalutran/Antagon) to prevent a premature LH surge: a case report

GnRH agonist for triggering final oocyte maturation in the GnRH antagonist ovarian hyperstimulation protocol: a systematic review and meta-analysis.

Increasing levels of estradiol are deleterious to embryonic implantation because they directly affect the embryo.

Review of clinical course and treatment of ovarian hyperstimulation syndrome (OHSS).

Use of gonadotrophin-releasing hormone agonists to trigger ovulation.

Impact of ovarian stimulation on corpus luteum function and embryonic implantation.

Triggering with human chorionic gonadotropin or a gonadotropin-releasing hormone agonist in gonadotropin-releasing hormone antagonist-treated oocyte donor cycles: findings of a large retrospective cohort study.

Triggering with HCG or GnRH agonist in GnRH antagonist treated oocyte donation cycles: a randomised clinical trial.

Luteolysis induced by a gonadotropin-releasing hormone agonist is the key to prevention of ovarian hyperstimulation syndrome.

Preliminary clinical outcome of novel strategy for the maximization of cumulative pregnancy rates per retrieval in normal responders

P31

scholarly article

P3181

4661756

http://www.w3.org/2001/XMLSchema#string

P356

10.1002/14651858.CD008046.PUB4

http://www.w3.org/2001/XMLSchema#string

P50

Madelon van Wely

Fulco Van der Veen

P577

2014-10-31T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25358904

http://www.w3.org/2001/XMLSchema#string